Enlivex Therapeutics Ltd. (NASDAQ: ENLV) Stock Information | RedChip
Enlivex Therapeutics Ltd. NASDAQ: ENLV logo small-cap
NASDAQ: ENLV

Enlivex Therapeutics Ltd.

$1.28 +0.0300 0% 133.2K

Meet The Management Team


Shai Novik
Shai Novik

Executive Chairman

Oren Hershkovitz, Ph.D.
Oren Hershkovitz, Ph.D.

Chief Executive Officer

Prof. Dror Mevorach, M.D.
Prof. Dror Mevorach, M.D.

Co-Founder & Scientific Adviser

Shachar Shlosberger
Shachar Shlosberger

CFO

Einat Galamidi, M.D.
Einat Galamidi, M.D.

VP Medical

Veronique Amor-Baroukh, Ph.D.
Veronique Amor-Baroukh, Ph.D.

Senior Director of Operations

Iris Tavor
Iris Tavor

Senior Director of Quality & Regulatory Affairs

Chen Ankri, Ph.D.
Chen Ankri, Ph.D.

Director of Pre-Clinical & Clinical Pharmacology

Sigal Arad
Sigal Arad

Director of Human Resources

Sign Up For ENLV Email News Alerts

First Name*
Last Name*
Phone*
Email*

*I agree to receive communications by text message about updates related to companies and/or industries I’ve expressed interest in. You may opt out by replying STOP or reply HELP for more information. Message frequency varies. Message and data rates may apply. You may review our Privacy Policy to learn how your data is used.

Disclosure

RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.

RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.

Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.

We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.

Enlivex Therapeutics (ENLV) is a client of RedChip Companies, Inc. ENLV agreed to pay RedChip Companies, Inc. an $8,000 monthly cash fee, beginning in February 2024, plus 25,000 warrants with an exercise price of $3.25 and 25,000 warrants with an exercise price of $4.25, for six month of investor awareness services. All warrants have a term of three years from date of issuance. ENLV also agreed to pay RedChip a one-time $50,000 fee for a national TV ad campaign aired September 11 to September 25, 2024, a one-time $37,500 fee for a national TV ad campaign aired October 14 to October 25, 2024, and a one-time $37,500 fee for a national TV ad campaign aired December 4 to December 17, 2024.

Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.